Abstract: Disclosed herein is a stable oxytocin composition having between about 0.04 and 0.08 IU/mL of oxytocin and/or a pharmaceutically acceptable salt thereof, a buffer comprising sodium acetate trihydrate and acetic acid, a tonicity adjusting agent comprising sodium chloride, a pH adjusting agent comprising acetic acid, sodium hydroxide, or a combination thereof, and water, the composition having a total impurities concentration of equal to or less than 16% after storage of at least six months at 25° C. Also disclosed herein is a pharmaceutical product having a single-use container containing the sterile and storage-stable liquid composition of the present disclosure.

Abstract: The present invention provides a stable, aqueous solution comprising a non-steroidal anti-inflammatory drug (NSAID) such as bromfenac or a pharmacologically acceptable salt or a hydrate thereof and a solubilizer. The present invention provides methods to reduce the level of degradation of bromfenac with the addition of pharmaceutically acceptable solubilizers other than an alkyl aryl polyether alcohol type polymer such as tyloxapol, and/or a polyethylene glycol fatty acid ester such as polyethylene glycol monostearate. Also provided are stabilized compositions, and methods of their manufacture and use, e.g., for the treatment of ocular inflammation and pain after cataract surgery.